On Demand webinar: 40% of men with type 2 diabetes have symptomatic testosterone deficiency – why are we still not finding and treating these men?
In the fourth of our 2022 ABCD webinar series, please join Dr Bob Ryder and Professor Hugh Jones to discuss symptomatic testosterone deficiency.
40% of men with type 2 diabetes have symptomatic testosterone deficiency. Testosterone deficiency is associated with an adverse effect on cardiovascular risk factors, osteoporosis and psychological wellbeing amongst other issues. Testosterone deficiency is also associated with an increased mortality in type 2 diabetes. Testosterone replacement has been shown to improve insulin resistance, lower HbA1c, lower cholesterol, reduce body weight, reduce mortality and make the patient feel better.
In this webinar we will provide the scientific data behind the information just given and also explain with examples the benefits of the ABCD nationwide audit programme with explanation and encouragement as to why clinicians should change their practice to try and identify their patients with symptomatic testosterone deficiency and enter them into the ABCD worldwide audit of testosterone deficiency in men with type 2 diabetes.
Q& A will follow this presentation
3
Speakers
-
Professor Thomas Hugh Jones
Consultant
Hugh is Honorary Professor of Andrology in the Department of Human Metabolism the University of Sheffield Medical School, Sheffield, UK and Hon. Consultant Endocrinologist at the Royal Hallamshire Hospital, Sheffield. He is a clinical and laboratory researcher into the role of testosterone in the pathogenesis and treatment of type 2 diabetes and cardiovascular disease. He has also conducted research on the hypothalamic and paracrine control of anterior pituitary hormone secretion, among others. 'Professor Jones is President of the Androgen Society (International). He is also on the European Association of Urology guideline committee for Sexual and Reproductive Health and also the British Society for Sexual Medicine guideline committee for the Management of Testosterone Deficiency. He was also on the International Consultation on Men' Health and Infertility. He was the first to demonstrate the following (1) the high prevalence of symptomatic testosterone deficiency in men with type 2 diabetes, (2) testosterone replacement improves insulin resistance, (3) reduces mortality in hypogonadal men with type 2 diabetes and (4) recently shown testosterone replacement has benefits on quality of life in these men. -
Dr. Dinesh Nagi
Consultant in Diabetes & Endocrinology
Dr Dinesh Nagi is currently working as an Honorary Consultant in Diabetes and endocrinology at Pinderfields Hospital Wakefield. Having served as Chairman of the ABCD between 2017-2020, he has recently taken up the role of Vice-Chairman of the DCT (Diabetes Care Trust) UK, a charitable trust which works closely with the ABCD. His main interest in diabetes was to promote Integrated Diabetes Care among Primary and Specialist Diabetes Services. -
Dr. Bob Ryder
Consultant Diabetologist
Bob Ryder trained in South Wales and Sheffield. He has worked as a Consultant Physician/Diabetologist/Endocrinologist, City Hospital, Birmingham since 1991. Over the years special interests have included diabetic retinopathy screening; diabetic hypoglycaemia unawareness; diabetic autonomic neuropathy; diabetic impotence; clinical use of IT; treating to target; relative risks and benefits of pioglitazone He leads the ABCD nationwide audits of new therapies and devices – current audits include SGLT2i, FreeStyle Libre, semaglutide, COVID 19 and diabetes, testosterone, closed-loop systems, oral semaglutide and Omnipod. He is chief investigator of two ABCD Endobarrier studies (https://youtu.be/xRcnMBOdb58, https://youtu.be/y1zm0Scq6YM). Beyond diabetes he is best known as principal author of best-selling "An Aid to the MRCP Short Cases", the 4th-edition of which is the three volume “An Aid to the MRCP PACES”.
